Description: Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand name for human therapeutic use in Australia. Its lead therapeutic product candidate is CYP-001, which is in Phase I clinical trial for the treatment of graft versus host disease. The company also develops products for the treatment of heart attack, asthma, acute respiratory distress syndrome, diabetic wounds, coronary artery disease, brain cancer, and critical limb ischaemia, which are in preclinical model. The company has a partnership with Monash University, Critical Care Research Group, University of Sydney, Department of Neurosurgery at Brigham and Women's Hospital - Harvard Medical School, the Cooperative Research Centre for Cell Therapy Manufacturing, University of New South Wales, and the Royal College of Surgeons Ireland to develop stem cell therapies. It also has a strategic partnership with Fujifilm Corporation of Japan for the development and research of Cymerus technology. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was founded in 2011 and is based in Carlton, Australia.
Home Page: www.cynata.com
100 Cubitt Street
Cremorne,
VIC
3121
Australia
Phone:
61 3 7067 6940
Officers
| Name | Title |
|---|---|
| Dr. Ross Alexander MacDonald Ph.D. | MD, CEO & Exec. Director |
| Dr. Kilian Kelly | Chief Operating Officer |
| Dr. Jolanta Airey | Chief Medical Officer |
| Dr. Suzanne Lipe | VP of Alliance Management |
| Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D., MAICD | Company Sec. |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.6577 |
| Price-to-Sales TTM: | 5.5316 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |